306 related articles for article (PubMed ID: 35080978)
1. Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges.
Sanz-Garcia E; Zhao E; Bratman SV; Siu LL
Sci Adv; 2022 Jan; 8(4):eabi8618. PubMed ID: 35080978
[TBL] [Abstract][Full Text] [Related]
2. Current Perspectives on Circulating Tumor DNA, Precision Medicine, and Personalized Clinical Management of Cancer.
Oliveira KCS; Ramos IB; Silva JMC; Barra WF; Riggins GJ; Palande V; Pinho CT; Frenkel-Morgenstern M; Santos SEB; Assumpcao PP; Burbano RR; Calcagno DQ
Mol Cancer Res; 2020 Apr; 18(4):517-528. PubMed ID: 31996469
[TBL] [Abstract][Full Text] [Related]
3. Dynamic Treatment Stratification Using ctDNA.
Vidal J; Taus A; Montagut C
Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
[TBL] [Abstract][Full Text] [Related]
4. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
Chen X; Wang L; Lou J
Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor DNA: current challenges for clinical utility.
Dang DK; Park BH
J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35703177
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
Cheng F; Su L; Qian C
Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor DNA in cancer diagnosis, monitoring, and prognosis.
Saha S; Araf Y; Promon SK
J Egypt Natl Canc Inst; 2022 Feb; 34(1):8. PubMed ID: 35187602
[TBL] [Abstract][Full Text] [Related]
8. Roles of circulating tumor DNA in PD-1/PD-L1 immune checkpoint Inhibitors: Current evidence and future directions.
Liu Z; Han Y; Dang Q; Xu H; Zhang Y; Duo M; Lv J; Li H; Kong Y; Han X
Int Immunopharmacol; 2022 Oct; 111():109173. PubMed ID: 35998502
[TBL] [Abstract][Full Text] [Related]
9. Ultrasensitive circulating tumor DNA analysis enables precision medicine: experimental workflow considerations.
Andersson D; Kristiansson H; Kubista M; Ståhlberg A
Expert Rev Mol Diagn; 2021 Mar; 21(3):299-310. PubMed ID: 33683971
[No Abstract] [Full Text] [Related]
10. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
[TBL] [Abstract][Full Text] [Related]
11. Utilizing circulating tumour DNA in radiation oncology.
Rostami A; Bratman SV
Radiother Oncol; 2017 Sep; 124(3):357-364. PubMed ID: 28735685
[TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor DNA in Cancer Management: A Value Proposition.
Lam WKJ
J Appl Lab Med; 2020 Sep; 5(5):1017-1026. PubMed ID: 32830269
[TBL] [Abstract][Full Text] [Related]
13. Enrichment and Analysis of ctDNA.
Gilson P
Recent Results Cancer Res; 2020; 215():181-211. PubMed ID: 31605230
[TBL] [Abstract][Full Text] [Related]
14. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.
Arisi MF; Dotan E; Fernandez SV
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259
[TBL] [Abstract][Full Text] [Related]
15. Genetic profiling of cancer with circulating tumor DNA analysis.
Lu L; Bi J; Bao L
J Genet Genomics; 2018 Feb; 45(2):79-85. PubMed ID: 29502957
[TBL] [Abstract][Full Text] [Related]
16. Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy.
Sivapalan L; Murray JC; Canzoniero JV; Landon B; Jackson J; Scott S; Lam V; Levy BP; Sausen M; Anagnostou V
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657818
[TBL] [Abstract][Full Text] [Related]
17. Use of Circulating Tumor DNA for Cancer Immunotherapy.
Snyder A; Morrissey MP; Hellmann MD
Clin Cancer Res; 2019 Dec; 25(23):6909-6915. PubMed ID: 31285372
[TBL] [Abstract][Full Text] [Related]
18. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.
Pascual J; Attard G; Bidard FC; Curigliano G; De Mattos-Arruda L; Diehn M; Italiano A; Lindberg J; Merker JD; Montagut C; Normanno N; Pantel K; Pentheroudakis G; Popat S; Reis-Filho JS; Tie J; Seoane J; Tarazona N; Yoshino T; Turner NC
Ann Oncol; 2022 Aug; 33(8):750-768. PubMed ID: 35809752
[TBL] [Abstract][Full Text] [Related]
19. Leveraging the Fragment Length of Circulating Tumour DNA to Improve Molecular Profiling of Solid Tumour Malignancies with Next-Generation Sequencing: A Pathway to Advanced Non-invasive Diagnostics in Precision Oncology?
Underhill HR
Mol Diagn Ther; 2021 Jul; 25(4):389-408. PubMed ID: 34018157
[TBL] [Abstract][Full Text] [Related]
20. A clinician's handbook for using ctDNA throughout the patient journey.
Hasenleithner SO; Speicher MR
Mol Cancer; 2022 Mar; 21(1):81. PubMed ID: 35307037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
